Merck and Pfizer receive positive opinion for Orphan Drug Designation for Avelumab
Merck and Pfizer announced the EMA’s Committee for Orphan Medicinal Products has issued a positive opinion for Orphan Drug designation for avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, pending an official decision by the EC, expected in December. November 25, 2015